

LabCorp (LH)

\$182.33 (As of 02/07/20)

Price Target (6-12 Months): **\$191.00**

Long Term: 6-12 Months

Zacks Recommendation:
Neutral

(Since: 02/08/19)

Prior Recommendation: Underperform

Short Term: 1-3 Months

Zacks Rank: (1-5)

4-Sell

Zacks Style Scores:

VGM:B

Value: B

Growth: C

Momentum: C

Summary

Over the past six months, shares of LabCorp have outpaced its industry. Its Diagnostics grew organically in terms of both revenue and volume despite additional price reductions due to PAMA and the loss of exclusivity in two managed care contracts. In the last reported quarter, it also exhibited strong underlying and organic growth across its Drug Development business banking on solid execution of three fundamental strategies. The recently-completed business swap transaction with Envigo also buoys optimism. LabCorp put up a robust show in the third quarter of 2019 with better-than-expected results. However, the disposition of businesses and the implementation of the PAMA dented growth. Unfavorable currency transaction continues to remain as a major headwind. The company expects the rest of 2019 to continue to witness similar hurdles.


Price, Consensus & Surprise



Data Overview

52 Week High-Low	\$185.50 - \$140.53
20 Day Average Volume (sh)	657,501
Market Cap	\$17.7 B
YTD Price Change	7.8%
Beta	1.07
Dividend / Div Yld	\$0.00 / 0.0%
Industry	Medical - Dental Supplies
Zacks Industry Rank	Top 33% (85 out of 254)

Sales and EPS Growth Rates (Y/Y %)



Last EPS Surprise	2.1%
Last Sales Surprise	0.7%
EPS F1 Est- 4 week change	-0.1%
Expected Report Date	02/13/2020
Earnings ESP	-0.6%
P/E TTM	16.6
P/E F1	15.3
PEG F1	1.8
P/S TTM	1.6

Sales Estimates (millions of \$)

	Q1	Q2	Q3	Q4	Annual*
2020	2,904 E	2,991 E	3,024 E	3,028 E	11,925 E
2019	2,791 A	2,882 A	2,929 A	2,928 E	11,531 E
2018	2,848 A	2,866 A	2,831 A	2,788 A	11,333 A

EPS Estimates

	Q1	Q2	Q3	Q4	Annual*
2020	\$2.71 E	\$3.13 E	\$3.04 E	\$3.01 E	\$11.94 E
2019	\$2.62 A	\$2.93 A	\$2.90 A	\$2.80 E	\$11.25 E
2018	\$2.78 A	\$2.98 A	\$2.74 A	\$2.52 A	\$11.02 A

*Quarterly figures may not add up to annual.

The data in the charts and tables, including the Zacks Consensus EPS and Sales estimates, is as of 02/07/2020. The reports text is as of 02/10/2020.



Overview

Headquartered in Burlington, NC, Laboratory Corporation of America Holdings or LabCorp is a leading healthcare diagnostics company, providing comprehensive clinical laboratory services and end-to-end drug development support.

In 2015, LabCorp acquired NJ based Covance, a drug development services company providing a wide range of early stage and late stage product development services on a worldwide basis primarily to the pharmaceutical and biotechnology industries. With this, currently LabCorp reports under two operating segments:

LabCorp Diagnostics (62% of total revenues in 2018): Includes LabCorp's legacy business except for its clinical trial services business, which is now part of Covance Drug Development, and includes the nutritional chemistry and food safety business, which was previously part of Covance. This business registered 2.5% revenue growth in 2018 from the year-ago period.

Covance Drug Development (38%): Includes Covance's legacy business except for its nutritional chemistry and food safety business, which is now part of LabCorp Diagnostics, and includes LabCorp's legacy clinical trial services business. This business reported 24.9% revenue growth in 2018.



Company Strategy

LabCorp has adopted a five-pillar strategy to achieve growth in its businesses . These five strategic pillars are:

- Deploy capital to investments
- Enhance IT capabilities to improve physician, patient experience
- Improve efficiency to remain the most efficient and highest value provider of laboratory services
- Continue scientific innovation to offer tests at reasonable pricing
- Development of alternative delivery models to improve patient outcome and reduce cost of care



Reasons To Buy:

- ▲ **Share Price Movement:** Over the past six months, shares of LabCorp increased 11.2% against the industry's 4.9% fall. LabCorp exited the third quarter on a strong note, with better-than-expected results. In third-quarter 2019, the company reported strong underlying performance and organic revenue growth across both Diagnostics and Drug Development businesses banking on solid execution of three fundamental strategies which are delivering advanced diagnostics, bringing new medicines to patients faster and using technology to improve patient care. During the quarter, Diagnostics business grew organically in terms of both revenue and volume despite additional price reductions due to Protecting Access to Medicare Act (PAMA) and the loss of exclusivity in two of the company's largest managed care contracts. Within Diagnostics, the company registered strong revenue per requisition and solid execution of its LaunchPad 2 initiatives.

Covance Drug Development also grew organically despite adverse impact of foreign currency translation. Of late, the company enhanced Covance's offerings through strategic acquisitions like MI Bioresearch that brings specialized preclinical capabilities in cell and gene therapy and oncology testing. The company is also hopeful about its recently-completed business swap transaction with Envigo. The transaction provides Covance with enhanced global non-clinical research capabilities, while maintaining access to a bigger research models and services through a multi-year renewable supply agreement. Right now, LabCorp is on track to deliver \$10 million of net costs in synergies from the integration and Envigo by the end of 2021. This apart, the Covance LaunchPad initiative is well on track to deliver \$150 million of net savings by the end of 2020.

- ▲ **Covance Drug Development Expands Well:** LabCorp's Covance Drug Development is the only CRO to combine early development, central lab and clinical services in an end-to-end offering. Under this business, LabCorp is full on force to expand the company's range of diagnostic offerings and create a new industry leader in both laboratory testing and CRO spaces who will act as a leading provider of medical testing besides operating as a premier full-service drug development organization. Chiltern integration has significantly strengthened the company's strategic position in clinical development and is accelerating revenue and profit growth within Covance.

In this regard, of late, LabCorp is enhancing Covance's offerings through strategic acquisitions. The acquisition of MI Bioresearch is expected to create opportunity for Covance to move from preclinical to clinical development. We are also optimistic about the company's plans to acquire Regulatory and Clinical Research Institute (RCRI), a device focused CRO with strong regulatory consulting expertise. This apart, in June, the company completed an innovative business swap transaction with Envigo.

In addition, the company has progressed with the Covance LaunchPad initiative. At the end of the third quarter 2019, LabCorp remains on track to deliver \$150 million of net savings from Covance LaunchPad by the end of 2020. This apart, the company has completed the \$30 million in cost synergies from the integration of Chiltern that it had committed to deliver in 2020 and expects to achieve \$10 million in net cost synergies from the integration of Envigo by the end of 2021.

- ▲ **LaunchPad in Diagnostics May Help Rebound Growth:** On the heels of a successful execution of the company's LaunchPad cost saving initiative in its drug development business, LabCorp has now introduced this program within its Diagnostics arm which is facing severe headwinds over the recent term. This Phase II of LaunchPad initiative in Diagnostics is expected to deliver \$200 million of savings by the end of 2021. This initiative focuses on eliminating manual processes; digitizing the business; using technology to improve quality, operations and service; enhancing the consumer experience and bringing LabCorp's services closer to the customer. Phase II of LaunchPad is expected to streamline its business, unlock new avenues for growth and contribute to improvement in the long-term margins.

- ▲ **Meaningful Acquisitions to Add Value:** LabCorp continues to add complementary capabilities through targeted acquisitions. The latest in the list is an innovative business swap transaction with Envigo, a provider of nonclinical contract research services and research models. In this transaction, the company has purchased Envigo's non-clinical contract research service business, while sell them Covance Research Products business. The company also enhanced its value by acquiring the diagnostic clinical laboratory testing business of South Bend Medical Foundation (SBMF), considerably enhancing the scope of local services that LabCorp offers to hospitals, physicians, and patients across Indiana, Michigan, Ohio, and Illinois.

- ▲ **Strategic Plans to Drive Growth:** As part of its three key strategic plans, LabCorp is working hard on new innovations with academic institutions in order to capture the growing lab testing market with its advanced assays and tools. In Diagnostics, the company successfully continues to provide the foundation for new collaborations with health systems, large physician groups and managed care partners. LabCorp has also created growth opportunities in women's health, medical drug monitoring, genetics and oncology testing, as well as in critical collaborations with players like Walgreens and 23andMe. Also, its partnerships with UnitedHealthcare and Aetna have helped LabCorp to become a contracted laboratory provider for all major national plans.

Within Covance Drug Development, the company's ongoing strategic investments in precision medicine, therapeutic expertise, FSP solutions and biologic drug development capabilities continue to increase its win rate with existing partners and new customers. The acquisition of Chiltern is significantly strengthening LabCorp's strategic position in clinical development and accelerating revenue and profit growth within Covance. This apart, the company's recent strategic technology contract with QIAGEN is expected to garner positive outcome down the line.

- ▲ **Progress on Strategic Collaborations:** LabCorp has strengthened its foothold in the diagnostics space through both organic and inorganic means and plans to collaborate with leading companies and academic institutions to provide a wider portfolio of tests. Among the company's recent alliances, worth mentioning are the company's team ups with UnitedHealthcare and Aetna which have helped LabCorp to become a contracted laboratory provider for all major national plans. Jul 1, 2019 onward, all of the LabCorp brands are included in the UnitedHealthcare's preferred lab network. The company is optimistic about the opportunity to grow volume with UnitedHealthcare through the PLN in 2020 and beyond. Further, in the third quarter, LabCorp partnered with the New Jersey Primary Care Association, which represents 23 community health centers. It has also finalized several new partnerships with health systems in the quarter. The company is also progressing well under its broad collaboration agreement with Walgreens on patient engagement, health and wellness offerings and creation of a next-generation CRO.

The solid revenue and earnings outlook for 2019 holds optimism indicating improving industry trends along with ongoing positive synergy from the Covance integration.

▲ **Stable Liquidity Position:** LabCorp is well capitalized having exited the third quarter 2019 with cash and cash equivalents of \$361.1 million compared with \$265.4 million at the end of the second quarter. The company has been using its cash balance to make strategic acquisitions and has been rewarding its shareholders through share repurchases. LabCorp noted interest in acquisitions in the field of contract research and pathology, including hematopathology, at an attractive valuation. During the third quarter, the company returned \$100 million to shareholders via share repurchases. LabCorp currently has \$950 million of authorization remaining under its existing share buyback plan.

The company's cash flow trends also remain robust. year to date, Year to date, operating cash flow was \$874.9 million, up from \$819 million in the year-ago period. Additionally, free cash flow was at \$602.9 million in the quarter, up from \$561.4 million a year ago.

In addition, free cash flow guidance for 2019 has been anticipated in the band of \$950 million-\$1.05 billion. Going forward, LabCorp expects to deploy half of the free cash flow to acquisitions and half to share buybacks.

Reasons To Sell:

▼ **Exposed to Currency Headwind:** With LabCorp deriving a huge share of its revenues internationally, it remains highly exposed to currency fluctuations. Unfavorable currency movements have been a major dampener over the last few quarters, as in the case of other important MedTech players too. While the trend has shown some sort of improvement in the reported quarter, sustainability remains a matter of question. In the third quarter, revenue dropped 30 basis points on account of unfavorable foreign currency translation. The 2019 guidance assumes a negative impact of 60 basis points from currency translation.

▼ **Competitive Landscape:** LabCorp faces intense competition from its major competitor, Quest Diagnostics, and other commercial laboratories and hospitals. In a \$55 billion U.S. lab market, hospitals control an estimated 55% of the diagnostic test market, compared to LabCorp's 10% share. While pricing is an important factor in choosing a testing lab, hospital-affiliated physicians expect a high level of service, including accurate and rapid turnaround of testing results. As a result, LabCorp and other commercial labs compete with hospital-affiliated labs primarily on the basis of quality of service.

▼ **Reimbursement Cut to Have a Negative Impact:** Changes in governmental regulations had a significant impact on LabCorp's operations. Particularly, in the last couple of years, the company faced several reimbursement issues hurting its revenues. The company is concerned about the CMS' (Centers for Medicare & Medicaid Services) latest Medicare reimbursement reduction as a result of the implementation of Protecting Access to Medicare Act (PAMA). Notably, 2018 was the opening year operating under the clinical IP schedule.

We are quite apprehensive about the entire scenario. With latest clinical lab fee schedule getting implemented without any amendment in favor of the testing laboratories, the benefit from Chiltern, the benefit from PAML and Mount Sinai and the Covance LaunchPad process are also getting offset to PAMA reductions.

The year 2019 is so far challenging for LabCorp due to the ongoing impact of PAMA. In the second quarter, the company announced significant revenue loss on lower Medicare pricing as a result of the implementation of PAMA. More specifically, PAMA had 90 basis points negative impact on LabCorp's top line during this period.

The current economic uncertainty including challenging volume environment for testing laboratories and utilization weaknesses are looming headwinds.

Last Earnings Report

Business Disposition and Currency Translation Dent LabCorp's Growth in Q3

Laboratory Corporation of America Holdings or LabCorp, reported third-quarter 2019 adjusted earnings per share of \$2.90, up 5.8% from the year-ago quarter. Also, the bottom line surpassed the Zacks Consensus Estimate by 2.1%.

On a GAAP basis, net earnings were \$2.25 per share, declining 27.4% from the year-earlier figure.

Revenues in the quarter under review grew 3.4% year over year to \$2.93 billion. The top line also beat the Zacks Consensus Estimate of \$2.91 billion by 0.7%.

The marginal year-over-year improvement was primarily led by 2.8% growth from acquisitions and 2.2% organic growth (which includes the negative impact of Protecting Access to Medicare Act or PAMA of 0.9%), partially offset by 1.3% negative impact of business dispositions and approximately 0.3% adverse foreign currency translation.

Quarter in Detail

LabCorp reports results under two operating segments — **LabCorp Diagnostics** and **Covance Drug Development**.

In the third quarter, **LabCorp Diagnostics** reported revenues of \$1.76 billion, reflecting a 0.4% uptick year over year. The upside primarily resulted from 0.9% organic growth and 0.8% favorable contribution from acquisitions, offset by 1.3% headwind from business dispositions. Organic revenue growth in the quarter included a 1.5% negative impact from the implementation of the PAMA.

Excluding business dispositions, the company witnessed 0.7% rise in total volume (measured by requisition) and 1% improvement in revenue per requisition in the third quarter.

Covance Drug Development's revenues improved 8.7% to \$1.18 billion in the third quarter. The upside was primarily attributed to 6% growth from acquisitions and 4.7% organic growth, partially offset by 0.8% adverse impact of foreign currency translation and business disposition of 1.2%.

Gross margin remained flat year over year at 27.9% in the reported quarter. Also, adjusted operating income rose 1.9% year over year to \$430.5 million. However, adjusted operating margin contracted 22 bps from the year-ago quarter to 21.5%.

LabCorp exited the third quarter with cash and cash equivalents of \$361.1 million compared with \$265.4 million at the end of the second quarter. Year to date, operating cash flow was \$874.9 million, up from \$819 million in the year-ago period. Additionally, free cash flow was at \$602.9 million in the quarter, up from \$561.4 million a year ago.

In the third quarter, the company returned \$100 million to shareholders via share repurchases. LabCorp currently has \$950 million of authorization remaining under its existing share buyback plan.

Outlook

The company has revised its 2019 guidance.

It now expects year-over-year revenue growth of 1.5-2% compared with 1-2% mentioned earlier. This includes a projected adverse impact of 1.5% from the disposition of businesses and a negative foreign currency movement of roughly 0.6%. The Zacks Consensus Estimate for revenues is pegged at \$11.48 billion for the current year.

Adjusted earnings per share estimate for 2019 has been narrowed to \$11.20-\$11.30 from \$11.10-\$11.40 mentioned earlier, indicating 1.6-2.5% rise from the 2018 adjusted earnings per share figure. The Zacks Consensus Estimate of \$11.29 for the same is close to the high end of the company's guidance.

Free cash flow is predicted to be \$950-\$1.05 billion (unchanged).

Quarter Ending 09/2019

Report Date	Oct 24, 2019
Sales Surprise	0.66%
EPS Surprise	2.11%
Quarterly EPS	2.90
Annual EPS (TTM)	10.97

Recent News

On **Jan 14, 2020**, LabCorp announced it will adopt the Ion Torrent Genexus System and OncoPrint Precision Assay for use in research and development of companion diagnostics as well as other future oncology and precision medicine applications. The potential for future deployment of the system and test across its network of laboratories and partner facilities will also be evaluated by LabCorp.

On **Jan 13, 2020**, LabCorp introduced its focused and coordinated suite of cell and gene therapy development solutions from Covance, its drug development business. These solutions are designed to reduce time and risk for sponsors at each phase and across the full continuum of their therapy development needs in one of the industry's fastest-growing segments.

Valuation

LabCorp shares are up 7.8% in the year to date period and up 26.4% in the trailing 12-month periods. Stocks in the Zacks sub-industry and Zacks Medical sector are up 1.9% and 2.2% in the year to date period, respectively. Over the past year, the Zacks sub-industry is down 3.5% and sector is up 4.7%.

The S&P 500 index is up 3.2% in the year to date period and up 21.9% in the past year.

The stock is currently trading at 15.2X Forward 12-months earnings, which compares to 17.7X for the Zacks sub-industry, 21.4X for the Zacks sector and 19.1X for the S&P 500 index.

Over the past five years, the stock has traded as high as 17.1X and as low as 10.8X, with a 5-year median 14.4X. Our Neutral recommendation indicates that the stock will perform in-line with the market. Our \$191 price target reflects 15.9x forward 12-months earnings.

The table below shows summary valuation data for LH.

Valuation Multiples - LH					
		Stock	Sub-Industry	Sector	S&P 500
P/E F12M	Current	15.15	17.68	21.40	19.12
	5-Year High	17.11	19.99	21.40	19.34
	5-Year Low	10.75	13.70	15.84	15.18
	5-Year Median	14.40	16.63	18.90	17.46
P/S F12M	Current	1.48	0.36	2.85	3.53
	5-Year High	1.69	0.36	3.82	3.53
	5-Year Low	1.06	0.23	2.44	2.54
	5-Year Median	1.41	0.28	2.95	3.00
P/B TTM	Current	2.45	4.51	4.59	4.29
	5-Year High	3.84	4.93	5.04	4.42
	5-Year Low	1.68	2.53	3.44	2.85
	5-Year Median	2.51	3.46	4.31	3.62

As of 02/07/2020

Industry Analysis Zacks Industry Rank: Top 33% (85 out of 254)



Top Peers

Align Technology, Inc. (ALGN)	Neutral
Bio-Rad Laboratories, Inc. (BIO)	Neutral
Quest Diagnostics Incorporated (DGX)	Neutral
DaVita Inc. (DVA)	Neutral
Exact Sciences Corporation (EXAS)	Neutral
Myriad Genetics, Inc. (MYGN)	Neutral
NeoGenomics, Inc. (NEO)	Neutral
OPKO Health, Inc. (OPK)	Neutral

Industry Comparison Industry: Medical - Dental Supplies				Industry Peers		
	LH Neutral	X Industry	S&P 500	DGX Neutral	EXAS Neutral	NEO Neutral
VGM Score	B	-	-	B	D	C
Market Cap	17.70 B	1.57 B	24.00 B	15.01 B	12.37 B	3.25 B
# of Analysts	9	5	13	9	8	5
Dividend Yield	0.00%	0.00%	1.78%	1.90%	0.00%	0.00%
Value Score	B	-	-	C	D	D
Cash/Price	0.02	0.06	0.04	0.08	0.10	0.05
EV/EBITDA	11.66	11.79	14.07	11.26	-126.04	98.87
PEG Ratio	1.79	1.99	2.04	2.21	NA	NA
Price/Book (P/B)	2.45	4.16	3.28	2.64	16.53	6.51
Price/Cash Flow (P/CF)	10.93	12.66	13.58	12.25	NA	96.36
P/E (F1)	15.35	21.11	18.86	16.71	NA	83.79
Price/Sales (P/S)	1.55	1.59	2.65	1.94	17.09	8.60
Earnings Yield	6.55%	3.68%	5.30%	5.98%	-0.43%	1.19%
Debt/Equity	0.93	0.32	0.71	0.70	0.67	0.24
Cash Flow (\$/share)	16.68	1.80	6.89	9.09	-0.99	0.32
Growth Score	C	-	-	B	D	B
Hist. EPS Growth (3-5 yrs)	11.29%	8.88%	10.80%	8.95%	NA	56.53%
Proj. EPS Growth (F1/F0)	6.10%	10.76%	7.23%	1.66%	75.29%	33.81%
Curr. Cash Flow Growth	9.98%	9.29%	9.51%	10.66%	20.69%	-21.26%
Hist. Cash Flow Growth (3-5 yrs)	14.10%	12.65%	8.55%	6.08%	NA	36.02%
Current Ratio	1.17	1.70	1.20	1.25	2.75	4.24
Debt/Capital	48.26%	26.85%	42.90%	41.55%	40.09%	19.56%
Net Margin	6.63%	4.08%	11.76%	11.10%	-29.84%	0.55%
Return on Equity	15.33%	15.72%	16.98%	16.15%	-29.06%	4.60%
Sales/Assets	0.66	1.02	0.54	0.64	0.42	0.62
Proj. Sales Growth (F1/F0)	3.41%	5.42%	4.15%	2.10%	87.43%	11.69%
Momentum Score	C	-	-	B	A	B
Daily Price Chg	-0.84%	-0.87%	-0.64%	-0.21%	0.35%	-0.73%
1 Week Price Chg	-1.00%	-1.10%	-2.60%	2.67%	4.14%	-0.22%
4 Week Price Chg	4.24%	4.76%	0.72%	4.95%	-7.99%	5.13%
12 Week Price Chg	7.63%	7.85%	4.69%	8.41%	20.24%	32.75%
52 Week Price Chg	23.65%	7.35%	16.01%	24.19%	9.77%	91.11%
20 Day Average Volume	657,501	318,989	1,961,054	873,378	2,232,337	850,019
(F1) EPS Est 1 week change	0.00%	0.00%	0.00%	-0.59%	0.92%	0.00%
(F1) EPS Est 4 week change	-0.07%	0.00%	-0.00%	-1.30%	2.41%	0.00%
(F1) EPS Est 12 week change	-0.10%	0.00%	-0.16%	-1.30%	11.64%	0.00%
(Q1) EPS Est Mthly Chg	-0.06%	0.00%	0.00%	-1.92%	7.89%	0.00%

Zacks Style Scores

The Zacks Style Score is as a complementary indicator to the Zacks rating system, giving investors a way to focus on the highest rated stocks that best fit their own stock picking preferences.

Academic research has proven that stocks with the best Value, Growth and Momentum characteristics outperform the market. The Zacks Style Scores rate stocks on each of these individual styles and assigns a rating of A, B, C, D and F. We also produce the VGM Score (V for Value, G for Growth and M for Momentum), which combines the weighted average of the individual Style Scores into one score. This is perfectly suited for those who want their stocks to have the best scores across the board.

Value Score	B
Growth Score	C
Momentum Score	C
VGM Score	B

As an investor, you want to buy stocks with the highest probability of success. That means buying stocks with a Zacks Recommendation of Outperform, which also has a Style Score of an A or a B.

Disclosures

This report contains independent commentary to be used for informational purposes only. The analysts contributing to this report do not hold any shares of this stock. The analysts contributing to this report do not serve on the board of the company that issued this stock. The EPS and revenue forecasts are the Zacks Consensus estimates, unless indicated otherwise on the reports first page. Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts personal views as to the subject securities and issuers. ZIR certifies that no part of the analysts compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report.

Additional information on the securities mentioned in this report is available upon request. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. Any opinions expressed herein are subject to change.

ZIR is not an investment advisor and the report should not be construed as advice designed to meet the particular investment needs of any investor. Prior to making any investment decision, you are advised to consult with your broker, investment advisor, or other appropriate tax or financial professional to determine the suitability of any investment. This report and others like it are published regularly and not in response to episodic market activity or events affecting the securities industry.

This report is not to be construed as an offer or the solicitation of an offer to buy or sell the securities herein mentioned. ZIR or its officers, employees or customers may have a position long or short in the securities mentioned and buy or sell the securities from time to time. ZIR is not a broker-dealer. ZIR may enter into arms-length agreements with broker-dealers to provide this research to their clients. Zacks and its staff are not involved in investment banking activities for the stock issuer covered in this report.

ZIR uses the following rating system for the securities it covers. **Outperform-** ZIR expects that the subject company will outperform the broader U.S. equities markets over the next six to twelve months. **Neutral-** ZIR expects that the company will perform in line with the broader U.S. equities markets over the next six to twelve months. **Underperform-** ZIR expects the company will underperform the broader U.S. equities markets over the next six to twelve months.

No part of this report can be reprinted, republished or transmitted electronically without the prior written authorization of ZIR.